Alnylam Pharmaceuticals Inc at UBS Global Healthcare Virtual Conference Transcript
Good afternoon, again. My name is Navin Jacob. I cover SMID cap biotech and large-cap pharma here at UBS. I'm happy to be here today with Alnylam Pharmaceuticals. And with -- and from Alnylam, I'm excited to have with us President and COO, Yvonne Greenstreet. Yvonne nice to have you here today.
Thanks, Navin. I'm really happy to be here as well. I mean just a few brief introductory remarks with respect to Alnylam. Many of you may know our story, but just to emphasize that we are the leader in RNAi therapeutics. We've been successful in bringing 4 RNAi medicines to market. And this is 3 that we are directly commercializing ourselves, ONPATTRO for hATTR amyloidosis patients with polyneuropathy, GIVLAARI for patients with acute hepatic porphyria and OXLUMO for the patients with primary hyperoxaluria type 1. And then one that's been commercialized by
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |